Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds bacterium or component thereof or substance produced...
Reexamination Certificate
2003-08-29
2009-08-11
Mondesi, Robert B (Department: 1645)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds bacterium or component thereof or substance produced...
C424S139100, C424S150100
Reexamination Certificate
active
07572449
ABSTRACT:
The use of (i) an antibody specific forYersinia pestisF1-antigen, or a binding fragment thereof, or (ii) an antibody specific forYersinia pestisV-antigen, or a binding fragment thereof, or a combination of (i) and (ii), in the production of a medicament for the treatment of infection byYersinia pestis. It has been found that such treatments are effective therapies forYersinia pestisinfection. In addition, the combination produces a synergistic effect when used prophylactically.
REFERENCES:
patent: 6248329 (2001-06-01), Chandrashekar et al.
patent: WO 95/18231 (1995-07-01), None
patent: WO 96/28551 (1996-09-01), None
patent: WO 00/73347 (2000-12-01), None
patent: WO 01/70200 (2001-09-01), None
Motin et al. (Infect. Immun., 62:4192-4201, 1994).
Greenspan et al. (Nature Biotechnology 17: 936-937, 1999).
Ellis (Chapter 29 of Vaccines, Plotkin, et al. (eds) WB Saunders, Philadelphia, 1988.
Bowie et al (Science, 1990, 247:1306-1310).
Anderson, et al., ‘Protection of Mice from Fatal Bubonic and Pneumonic Plague by Passive Immunization with Monoclonal Antibodies Against the F1 Protein ofYersinia pestis,’ Am. J. Trop. Med. Hyg., 56(4):471-473 (1997).
Anderson, et al., ‘Protection of Mice from Fatal Bubonic and Pneumonic Plague by Passive Immunization with Monoclonal Antibodies Against the F1 Protein ofYersinia pestis,’ Am. J. Trop. Med. Hyg., 56(4):471-473 (1997).
Casadevall, ‘Short Analytical Review Passive Antibody Therapies: Progress and Continuing Challenges,’Clinical Immunology, 93(1):5-15 (1999).
Cornelis, ‘Minireview TheYersiniaDeadly Kiss,’Journal of Bacteriology, 180(21):5495-5504 (1998).
de Haard, et al., ‘A Large Non-Immunized Human Fab Fragment Phage Library That Permits Rapid Isolation and Kinetic Analysis of High Affinity Antibodies,’Journal of Biological Chemistry, 274(26):18218-18230 (1999).
Du, et al., ‘Role of Fraction 1 Antigen ofYersinia pestisin Inhibition of Phagocytosis,’Infection and Immunity, 70(3):1453-1460 (2002).
Duplantier, et al., ‘Resurgence de la peste dans le district d'lkongo a Maagascar en 1998,’Bulletin De La Societe De Pathologie Exotique, 94(2):119-112 (2001).
Fields, et al., Virulence role of V antigen ofYersinia pestisat the bacterial surface,Infection and Immunity, 67(10):5395-5408 (1999).
Frank, et al., ‘Generation and Characterization of a Protective Monoclonal Antibody toPseudomonas aeruginosaPcrV,’Journal of Infectious Diseases, 186:64-73 (2002).
Green, et al., ‘The SCID/Beige mouse as a model to investigate protection againstYersinia pestis,’ FEMS Immunology and Medical Microbiology, 23(2):107-113 (1999).
Guiyoule, et al., ‘Recent Emergence of New Variants ofYersinia pestisin Madagascar,’Journal of Clinical Microbiology, 35(11):2826-2833 (1997).
Guiyoule, et al., ‘Transferable Plasmid-Mediated Resistance to Streptomycin in a Clinical Isolate ofYersinia pestis,’ Emerging Infectious Diseases, 7(1):43-48 (2001).
Heath, et al., ‘Protection against experimental bubonic and pneumonic plague by a recombinant capsulat F1-V antigen fusion protein vaccine,’Vaccine, 16(11/12):1131-1137 (1998).
Hill, et al., ‘Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens ofYersinia pestis,’ Infection and Immunity, 71(4):2234-2238 (2003).
Hill, et al., ‘Regions ofYersinia pestisV Antigen That contribute to Protection against Plague Identified by Passive and Active Immunization,’Infection and Immunity, 65(11):4476-4482 (1997).
Hueck, ‘Type III Protein Secretion Systems in Bacterial Pathogens of Animals and Plants,’Microbiology and Molecular Biology Reviews, 62(2):379-433 (1998).
Jones, et al., ‘Protective efficacy of a fully recombinant plague vaccine in the guinea pig,’Vaccine, 21:3912-3918 (2003).
Jones, et al., ‘Protection conferred by a fully recombinant sub-unit vaccine againstYersinia pestisin male and female mice of four inbred strains,’Vaccine, 19:358-366 (2001).
Keller, et al., ‘Passive Immunity in Prevention and Treatment of Infectious Diseases,’Clin. Microbiol. Rev., 13(4):602-614 (2000).
Knappik, et al., ‘Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL) Based on Modular Consensus Frameworks and CDRs Randomized with Trinucleotides,’Journal of Molecular Biology, 296:57-86 (2000).
Leary, et al., ‘Active Immunization with Recombinant V Antigen fromYersinia pestisProtects Mice against Plague,’Infection and Immunity, 63(8):2854-2858 (1995).
Leary, et al., ‘Expression of an F1/V fusion protein in attenuatedSalmonella typhimuriumand protection of mice against plague,’Microbial Pathogenesis, 23:167-179 (1997).
Mayers, et al., ‘Antitoxin therapy for botulinum intoxication,’Reviews in Medical Microbiology, 12(1):29-37 (2001).
Migliani, et al., ‘Resurgence de la peste dans le district d'lkongo a Madagascar en 1998,’Bulletin De La Societe De Pathologie Exotique, 94(2):115-118 (2001).
Motin, et al., ‘Suppression of Mouse Skin Allograft Rejection by Protein A-YersiniaeV Antigen Fusion Peptide,’Transplantation, 63(7):1040-1042 (1997).
Motin, et al., ‘Passive Immunity toYersiniaeMediated by Anti-Recombinant V Antigen and Protein A-V Antigen Fusion Peptide,’Infection and Immunity, 62(10):4192-4201 (1994).
Nakajima, et al., ‘Suppression of Cytokines in Mice by Protein A-V Antigen Fusion Peptide and Restoration of Synthesis by Active Immunization,’Infection and Immunity, 63(8):3021-3029 (1995).
Neuberger, et al., ‘Mice perform a human repertoire,’Nature, 386:25-26 (1997).
Nissim, et al., ‘Antibody fragments from a ‘single pot’ phage display library as immunochemical reagents,’Embo Journal, 13(3):692-698 (1994).
Perry, et al., ‘Yersinia pestis—Etiologic Agent of Plague,’Clinical Microbiology Reviews, 10(1):35-66 (1997).
Pettersson, et al., ‘The V-antigen ofYersiniais surface exposed before target cell contact and involved in virulence protein translocation,’Molecular Microbiology, 32(5):961-976 (1999).
Ratsitorahina, et al., ‘Epidemiological and diagnostic aspects of the outbreak of pneumonic plague in Madagascar,’Lancet, 355:111-113 (2000).
Rosqvist, et al., ‘Intracellular Targeting of theYersiniaYopE Cytotoxin in Mammalian Cells Unduces Actin Microfilament Disruption,’Infection and Immunity, 59(12):4562-4569 (1991).
Rosqvist, et al., ‘Target cell contact triggers expression and polarized transfer ofYersiniaYopE cytotoxin into mammalian cells,’Embo Journal, 13(4) :964-972 (1994).
Russell, et al., ‘A comparison of Plague vaccine, USP and EV76 vaccine induced protection againstYersinia pestisin a murine model,’Vaccine, 13(16):1551-1556 (1995).
Sawa, et al., ‘Active and passive immunization with thePseudomonasV antigen protects against type III intoxication and lung injury,’Nature Medicine, 5(4):392-398 (1999).
Shime, et al., ‘Therapeutic Administration of Anti-PcrV F(ab′)2in Sepsis Associated withPseudomonas aeruginosa,’ Journal of Immunology, 167:5880-5886 (2001).
Sing, et al., ‘Yersinia enterocoliticaEvasion of the Host Innate Immune Response by V Antigen-Induced IL-10 Production of Macrophases Is Abrogated in IL-10-Deficient Mice,’Journal of Immunology, 168:1315-1321 (2002).
Shivaji, et al., ‘Identification ofYersnia pestisas the causative organism of plague in India as determined by 16S rDNA sequencing and RAPD-based genomic fingerprinting,’FEMS Microbiology Letters, 189:247-252 (2000).
Taylor, et al., ‘Humanised monoclonal antibody to respiratory syncytial virus,’Lancet, 337:1411-1412 (1991).
Titball, et al., ‘Expression of theYersinia pestisCapsular Antigen (F1 Antigen) on the Surface of an aroA Mutant ofSalmonella typhimuriumInd
Hill James
Titball Richard William
Williamson Ethel Diane
Gangle Brian J
Kilpatrick & Stockton LLP
Mondesi Robert B
The Secretary of State for Defense in Her Britannic Majesty's Go
LandOfFree
Vaccine against Yersinia comprising one or two antibodies,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine against Yersinia comprising one or two antibodies,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine against Yersinia comprising one or two antibodies,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4115028